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Cancer can be defined as a deregulation or hyperactivity
in the ongoing network of intracellular and extracellular
signaling events. Reverse phase protein microarray tech-
nology may offer a new opportunity to measure and pro-
file these signaling pathways, providing data on post-
translational phosphorylation events not obtainable by
gene microarray analysis. Treatment of ovarian epithelial
carcinoma almost always takes place in a metastatic set-
ting since unfortunately the disease is often not detected
until later stages. Thus, in addition to elucidation of the
molecular network within a tumor specimen, critical ques-
tions are to what extent do signaling changes occur upon
metastasis and are there common pathway elements that
arise in the metastatic microenvironment. For individual-
ized combinatorial therapy, ideal therapeutic selection
based on proteomic mapping of phosphorylation end
points may require evaluation of the patient’s metastatic
tissue. Extending these findings to the bedside will require
the development of optimized protocols and reference
standards. We have developed a reference standard
based on a mixture of phosphorylated peptides to begin
to address this challenge. Molecular & Cellular Pro-
teomics 4:346–355, 2005.
Major discovery efforts brought about by advances in
genomic and proteomic technologies have resulted in many
new potential drug targets. Most of these new targets are
proteins involved in cellular signaling, and a number of
array-based technologies are being developed to assess
and validate these candidates (1–6). These emergent tech-
nologies provide the opportunity to measure the varying
activities of enzymatic networks in cell lines before and after
perturbation in vitro. However, these models may not accu-
rately recapitulate the activity of a protein-signaling network
within a cell in situ because these networks exist within the
context of the inter- and intracellular microenvironment.
Therefore, it is critical that protein array technologies be
developed to measure the status of kinase-driven molecular
networks as they exist within the context of the cellular
milieu in both normal and diseased tissues. Protein microar-
rays can be used to profile the working state of cellular
signal pathways in a manner not possible with gene mi-
croarrays since post-translational modifications cannot be
accurately portrayed by global gene expression patterns
alone (3, 7–20).
Unique and potentially revolutionary opportunities exist for
protein microarray technology. Because most new drug tar-
gets for cancer and many other diseases are signaling-re-
lated, a proteomic approach that can elucidate ongoing post-
translational phosphorylation events now makes it possible to
generate a diagnostic portrait, based on the activity of the
drug targets themselves, of who will respond to a particular
therapy and who will not. Thus, providing clinicians with
knowledge of which pathways are active in a patient’s tumor
will enable them to specifically apply targeted therapy. The
technology may also be used to monitor total and phospho-
rylated proteins over time, before and after treatment, or
between disease and non-disease states, allowing us to infer
the activity levels of the proteins in a particular pathway in real
time (21–25). Proteomic approaches to molecular network
analysis may provide more valuable clinical information than
just “response” analysis and is an enabling tool for true pa-
tient-tailored therapy.
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PROTEIN MICROARRAY FORMATS
Protein microarray formats can be divided into two major
classes: forward phase arrays and reverse phase arrays
(RPAs).1 In the forward phase array format, the analyte(s) of
interest is captured from the solution phase by a capture
molecule, usually an antibody, that is immobilized on a sub-
stratum and acts as bait molecule (1, 2) (Fig. 1). In a forward
phase array, each spot contains one type of immobilized
antibody or bait protein. Each array is incubated with one test
sample such as a cellular lysate or serum sample representing
a specific treatment condition, and multiple analytes from that
sample are measured simultaneously. In contrast, the RPA
format immobilizes an individual complex test sample in each
array spot such that an array is comprised of hundreds of
different patient samples or cellular lysates. In the RPA format,
each array is incubated with one detection protein (i.e. anti-
body), and a single analyte end point is measured and directly
compared across multiple samples (17, 24, 26–29) (Fig. 1).
Probing multiple arrays spotted with the same lysate concom-
itantly with different phosphospecific antibodies provides the
effect of generating a multiplex readout. Efforts are ongoing in
our laboratory to multiplex the arrays even further through the
use of dual color infrared dye-labeled antibodies as well as
quantum dots. Using these technologies, it is hoped that
multiple analytes can be measured on the same spot on the
same array (30, 31). The utility of reverse phase protein mi-
croarrays lies in their ability to provide a map of known cell
signaling proteins. Identification of critical nodes, or interac-
tions, within the network is a potential starting point for drug
development and/or the design of individual therapy regimens
(21, 22). The array format is also amenable to extremely
sensitive analyte detection (Fig. 2) with detection levels ap-
proaching attogram amounts of a given protein and variances
of less than 10% (1, 32). Detection ranges could be substan-
tially lower in a complex mixture such as a cellular lysate;
however, the sensitivity of the RPAs is such that low abun-
dance phosphorylated isoforms can still be measured from a
spotted lysate amount of less than 10 cell equivalents. This
level of sensitivity combined with analytical robustness is
critical if the starting input material is only a few hundred cells
from a biopsy specimen.
The reverse phase protein array has demonstrated a unique
ability to analyze signaling pathways using small numbers of
cultured cells or cells isolated by laser capture microdissec-
tion from human tissue procured during clinical trials (17, 24,
26, 27). Using this approach, microdissected pure cell popu-
lations are taken from human biopsy specimens, and a protein
lysate is arrayed onto nitrocellulose-coated slides (Fig. 3). Key
technological components of this method offer unique advan-
tages over tissue arrays (33) or antibody arrays (34, 35). First
the RPA can use denatured lysates so that antigen retrieval,
which is a large limitation for tissue arrays, is not problematic.
Protein microarrays can also consist of non-denatured lysates
derived directly from microdissected tissue cells so that pro-
tein-protein, protein-DNA, and/or protein-RNA complexes
can be detected and characterized. Each patient sample is
printed on the array in serial dilutions, providing an internal
standard. When an internal reference standard of known and
fixed amounts of the analyte are applied to the same array, a
direct and quantitative measurement of the phosphorylated
end point can be attained within the linear dynamic range of
the assay. Finally RPAs do not require direct labeling of the
patient sample as a readout for the assay, which provides a
marked improvement in reproducibility, sensitivity, and ro-
bustness of the assay over other techniques (36).
The RPA platform has been used to explore a variety of
signaling pathways involved in malignant progression and
tumor biology (17, 26–29, 37). For example, in a study of
prostate tissue, pathway profiling of microdissected cells from
normal, stroma, and prostate tumors revealed the preliminary
finding that activation of protein kinase C  is down-modu-
lated in prostate cancer progression (26). If validated, this
finding could have profound effects on the rationale behind
some current therapies (38) and illustrates the importance of1 The abbreviation used is: RPA, reverse phase array.
FIG. 1. Classes of protein microarray technology. Forward phase
arrays (top) immobilize a bait molecule such as an antibody designed
to capture specific analytes with a mixture of test sample proteins.
The bound analytes are detected by a second sandwich antibody or
by labeling the analyte directly (upper right). Reverse phase arrays
immobilize the test sample analytes (e.g. lysate from laser capture
microdissected cells) on the solid phase. An analyte-specific ligand
(e.g. antibody; lower left) is applied in solution phase. Bound antibod-
ies are detected by secondary tagging and signal amplification (lower
right).
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proteomic technology coupled to signal pathway profiling in
providing new and unexpected insights into cellular processes.
MAPPING MOLECULAR NETWORKS IN EPITHELIAL
OVARIAN CANCER
With these potentials in mind, we are elucidating the value of
RPAs in several types of human cancer tissues to gain insights
into potential novel therapeutic strategies. In particular, epithe-
lial ovarian cancer represents a clinical challenge for which
much remains to be discovered. Of all gynecological cancers, it
carries the worst prognosis primarily due to the late stage at
presentation. For the patient with advanced disease, cytoreduc-
tive surgery and cytotoxic chemotherapy with taxane and plat-
inum compounds will produce an initial response in the majority
of patients, but ultimately most will experience relapse or de-
velop drug resistance and consequently die of their disease (39).
As a result of poor outcome and inability to detect disease
confined to the organ, a lot of emphasis has been directed at
identifying new disease biomarkers, indicators of response to
therapy, and novel treatment options for patients with ad-
vanced or refractory disease. Newer chemotherapeutic
agents including topoisomerase I inhibitors and taxane ana-
logues may offer scope for defeating resistant neoplastic cells
(40). Furthermore our increasing knowledge of the molecular
biology of ovarian cancer coupled with advances in global
expression profiling has led to the development of novel tar-
geted therapies including monoclonal antibodies, small mol-
ecule inhibitors, gene therapy, selective hormonal agents, and
cytokines (40). For epithelial ovarian cancer, much emphasis
has been placed on developing agents that block epidermal
growth factor receptor signaling with either monoclonal anti-
body (cetuximab) (41) or small molecule inhibitors of the re-
ceptor tyrosine kinase (gefitinib) (42). Other innovative agents
undergoing trials that specifically target signal transduction
pathways directly associated with tumor growth and progres-
sion include bevacizumab (Avastatin), a monoclonal antibody
that inhibits vascular endothelial growth factor receptor (43),
and imatinib mesylate (Gleevec), a small molecule inhibitor of
three tyrosine kinases, Bcr-Abl, c-Kit, and platelet-derived
growth factor receptor (44). However, as a consequence of
the heterogeneous nature of ovarian cancer, the efficacy of
specific cancer agents will invariably only suit a subset of
patients and probably only at a particular stage of their dis-
ease. Given the multitude of molecular defects in ovarian
cancer, it is therefore necessary to profile multiple signal
transduction pathways simultaneously and define a carcino-
genic “fingerprint” specific to the patient. Novel agents can
then be selectively applied either alone or in combination with
other novel or existing treatments.
Our laboratories have a significant interest in defining and
tailoring combinations of new specific drug targets for pa-
tients with ovarian and other cancers using the reverse phase
arrays to characterize the activated state of cellular signaling
pathways in human patient biopsy material. At a molecular
level, the process of growth, invasion, and migration of neo-
plastic cells is driven by a substantial number of integrated
and interconnecting pathways that can be quantitatively and
sensitively detected in human tissue lysates using protein
microarray methodology (45). In a previous study, ovarian
cancer epithelial cells were microdissected by laser capture
(46), and the activation state of prosurvival and mitogenic
FIG. 2. Example of sensitivity and reproducibility analysis of the reverse phase protein microarrays. The first spot of A1 and C1 is 45
pg, and the first spot of B1 and D1 is 38 pg. Rows A and C are duplicates from dilutions for recombinant active Akt protein. Rows B and D
are duplicates from dilution for phospho-Akt (Ser-473) peptide. In each grid, the sample was diluted 2-fold from the first spot. Each dilution
was spotted in duplicates. From columns 1 to 10, each first spot is 2-fold diluted from the previous one. For example, the first spot of grid A1
is 45 pg, the first spot of grid A2 is 22.5 pg, and the first spot of grid A3 is 11.25 pg. The array was stained with phospho-Akt antibody (1:250
dilution).
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signaling pathways was evaluated to assess the profiles in
primary tumors at different stages of disease progression (27).
While the levels of phosphorylated extracellular signal-regu-
lated kinase 1/2 were higher in advanced stage tumors and in
those with endometrioid morphology in conjunction with Akt,
expression levels tended to be more patient-specific rather
than stage-specific (27). The findings exemplify the need to
develop patient-tailored therapy that blocks the signaling driv-
ing neoplastic progression at the time of treatment irrespec-
tive of the stage.
TARGETING THE METASTATIC OVARIAN TUMOR
Unlike other solid epithelial tumors, ovarian cancer spreads
initially by surface shedding into the peritoneal cavity followed
by invasive implantation. Approximately 70% of patients with
ovarian cancer present with International Federation of Gyn-
ecology and Obstetrics Stage III or IV disease, indicating that
they have metastatic dissemination to the peritoneum beyond
the pelvis (47). Accordingly prognosis of the majority patients
with ovarian cancer is governed by the behavior of the dis-
seminated metastatic cells and not by the primary tumor. Our
understanding of the signaling events that facilitate the de-
tachment, migration, and survival of neoplastic cells from the
primary tumor is not fully known, and whether these changes
are a cause or consequence of the metastatic process re-
mains to be determined. These answers are critical in identi-
fying specific targets for therapeutic intervention of advanced
metastatic disease.
FIG. 3. Application of reverse phase arrays in mapping molecular networks of ovarian cancer. A, using laser capture microdissection
(LCM), ovarian cancer epithelial cells were isolated under direct microscopic vision from stained tissue sections leaving residual stroma on the
slide. Approximately 25,000 cells were dissected for each case and lysed directly on the laser capture microdissection cap with extraction
buffer. One hundred arrays were printed on nitrocellulose-coated slides. H&E, hematoxylin and eosin. B, example of an ovarian cancer reverse
phase array probed for active extracellular signal-regulated kinase (ERK) signaling using a phosphospecific antibody detected with a
tyramide-based avidin/biotin amplification system. Samples are printed in two columns: the left column represents primary tumors, and the
right column represents metastatic lesions. Cases are printed in duplicate, five-point dilution curves to ensure the linear detection range for the
antibody concentration is achieved. The sixth point represents a negative control consisting of extraction buffer alone. A positive control lysate
(A431 squamous carcinoma cell line) is printed on the array for monitoring immunostaining performance. Phosphorylation-specific reference
peptides are printed in a 12-point dilution curve on the bottom of the array for comparative, precise quantification of patient samples between
arrays. pERK, phosphorylated extracellular signal-regulated kinase; EGF, epidermal growth factor. C, stained slides for the multiple phospho-
rylation-specific end points were scanned using Adobe Photoshop. Following total protein estimation with a Sypro Ruby stain, the intensity
values of each antibody were normalized to total protein, and dilution curves were generated using Microvigene software. Histograms could
then be generated to compare alterations in cell signaling between the primary and metastatic samples.
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As an adjunct to and extension of our previous study of
primary ovarian carcinoma (27), we utilized RPA technology to
profile a matched cohort of primary and metastatic ovarian
carcinomas. In characterizing signal pathway alterations be-
tween the two tissue microenvironments, we hoped to gain
insights into the aberrant signaling that maintains shed neo-
plastic ovarian cells at secondary sites. In collaboration with
the National Ovarian Cancer Early Detection Program (North-
western University Hospital, Chicago, IL), 15 frozen tissue
samples were obtained from nine patients with a diagnosis of
Stage III or IV epithelial ovarian cancer. Six patients had
matched primary ovarian tissue and omental metastases ob-
tained during cytoreductive surgery. The histological diag-
noses comprised papillary serous, endometrioid, and mixed
carcinomas and one primary peritoneal carcinoma. Epithelial
cells were microdissected from frozen tumor sections and
printed on the arrays as described previously (27) (Fig. 3). The
slides were probed with 26 phosphospecific antibodies to
proteins involved in mitogenesis including growth factor re-
ceptors, signal transducing proteins, and nuclear transcription
factors to profile the phosphoproteomic signal pathway
circuitry.
Analysis of multiple different kinase substrates detected by
phosphorylation-specific antibodies revealed a striking de-
gree of patient heterogeneity in the activity of the signaling
cascades within each patient. Unsupervised hierarchical clus-
tering analysis revealed that the samples were divided into
two large groups: one in which the majority of end points were
activated and the other in which they were not (Fig. 4). This
division was not based on primary or metastatic tissue origin
or by histologic type. Interestingly the primary peritoneal car-
cinoma did not have a significantly different phosphopro-
teomic portrait than the primary ovarian tumors. The second
observation was that comparison of cell signaling within the
primary group itself or the metastatic group demonstrated
considerable variation in the level of signal pathway activa-
tion; there was no common pattern specific to either of the
tissue microenvironments.
FIG. 4. Unsupervised hierarchical clustering analysis of multiplexed kinase substrate end points. The multiple different kinase
substrates are outlined on the horizontal axis, and the tissue phenotype is on the vertical axis. Higher relative levels of a phosphorylated
substrate are represented in red; lower levels are in green. Matched cases are labeled in the same color type on the vertical axis, and
unmatched cases are represented in black type. Met, metastatic tissue; cl Casp 3, cleaved Caspase 3; p, phosphorylated; ER, estrogen
receptor ; COX-2, cyclooxygenase-2; PKC, protein kinase C; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase; GSK3,
glycogen synthase kinase-3; mTOR, mammalian target of rapamycin; STAT, signal transducers and activators of transcription; EGFR,
epidermal growth factor receptor; MARCKS, myristoylated alanine-rich C kinase substrate; ERK, extracellular signal-regulated kinase.
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Finally perhaps the most intriguing finding was that the
metastatic signatures were dramatically changed compared
with their matched primary counterparts with entirely different
portraits emerging. Each patient’s proteomic pattern had
evolved as the tumor spread to a secondary site. In part, these
results are similar to our previous work in primary ovarian
cancers in that the patterns of activation in human ovarian
tumors may indeed be patient-specific. The additional discov-
ery that metastatic cell signaling is so dissimilar to the primary
tumor highlights the critical need for patient-tailored therapy
that is designed to specifically target the disseminated cells
as it is these aberrant pathways that most likely reflect the
behavior of the disease within the patient. In this small cohort,
each of these patients may have responded quite differently
to conventional chemotherapy despite being of similar dis-
ease stage. The acquired change in the tumor proteome may
indeed be associated with drug resistance. The question cur-
rently being addressed by our group is whether metastasis to
different secondary sites, e.g. liver or lung, shows the same
degree of signaling heterogeneity, demonstrating organ- or
patient-specific phosphorylation patterns.
The expression profile produced by the microarray experi-
ments represents a snapshot of the proteomic state of the
tissues from two distinct microenvironments. To pursue the
identification of specific targets that may separate primary
and metastatic tumors, we then applied principle component
analysis to identify end points that will segregate them from
each other. Principle component analysis is an analytic
method that identifies a subset of variables that is responsible
for the majority of the observed differences among data sets
(48). It has been used previously for data mining of both cDNA
(49) and tissue microarrays (50) to determine transcriptional
fingerprints underlying phenotypic variations. In our cohort,
principle component analysis identified several phosphoryl-
ated proteins that represented most of the variation between
primary and metastatic tissue expression patterns. These in-
cluded the phosphorylated forms of c-Kit, Ask, myristoylated
alanine-rich C kinase substrate, IB, and Ras-GRF. Using
partition analysis (51, 52), we then found that most of the
primary and metastatic tumors could be distinguished from
each other by phosphorylated c-Kit expression alone; 13 of
the 15 tissue samples could be categorized as either primary
or secondary origin (Fig. 5).
The c-kit gene encodes a transmembrane receptor tyrosine
kinase, a family of receptors that play important roles in the
regulation of cellular proliferation and differentiation (53). Its
expression and activation are well documented in a variety of
human tumors including gastrointestinal stromal tumors, leu-
kemias, germ cell tumors (53), and breast tumors (54). The
expression of c-Kit has been also described in epithelial ovar-
ian carcinoma, and although the data vary considerably, the
majority have shown elevated expression compared with nor-
mal ovary (55). Furthermore c-Kit correlates with advanced
stage and chemotherapy resistance in serous ovarian carci-
nomas (56). c-Kit expression represents one of the fine ex-
amples of how expression profiling has led to the develop-
ment of a selective tyrosine kinase inhibitor, imatinib mesylate
(Gleevec) (44).
To our knowledge, comparisons of phosphorylated c-Kit
expression in primary and metastatic ovarian tumors have not
been evaluated previously. Our results have revealed poten-
tially important insights into the most optimal and therapeutic
formula for advanced ovarian cancer. In this small study set,
the transition from primary to secondary site correlated with
activation of c-Kit; therefore these patients may specifically
benefit from Gleevec therapy. However, because the individ-
ual patients had such a heterogeneous pattern of activated
signals in other pathways, combination therapy with other
specific kinase inhibitors would have to be selectively applied
based on each phosphoproteomic fingerprint.
Clinical trials of Gleevec therapy are already underway for
ovarian cancer (40). RPA technology could be an effective
method of stratifying patients who may benefit from therapy
or for comparing pre- and post-treatment proteomic patterns
in patients who are c-Kit-positive. For patients with resistant
or refractory disease, an entirely different therapeutic regime
may then be chosen based on their activated kinome state.
It is clear, based on these aforementioned case studies,
that reverse phase protein microarray technology can gener-
ate important and enabling data. However, circumspection is
clearly warranted as the translation of intriguing research find-
ings into clinical implementation is fraught with the challenges
of reproducibility, standardization, and clinical validation.
What technological advances and method developments are
required before phosphoproteomics-based molecular net-
work analysis of patient tissue is being routinely performed at
FIG. 5. Analysis of phosphorylated c-Kit by tissue origin. Shown
is the one-way analysis of normalized relative intensity values for
phospho-c-Kit (pcKIT) demonstrating segregation of primary and
metastatic tissue origins by this end point.
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the bedside and the results are used for therapeutic decision
making?
CHALLENGES FOR PROTEIN MICROARRAY USE AT THE BEDSIDE
The field of gene expression profiling was catalyzed by the
ease and throughput of manufacturing probes with known,
specific, and predictable affinity constants. In contrast, the
probes (e.g. antibodies, aptamers, ligands, and drugs) used
for protein microarrays cannot be manufactured with predict-
able affinity and specificity. The availability of high quality,
specific antibodies or suitable protein binding ligands is a
major limiting factor and starting point for the successful
utilization of this technology (4). Post-translational modifica-
tions or protein-protein interactions of an individual protein
will contain critical biological meaning that cannot be ascer-
tained merely by measuring the total concentration of the
analyte. Consequently a significant challenge for protein mi-
croarrays is the need for antibodies or similar detection
probes that are specific for the modification or activation state
of the target protein.
Antibody specificity must also be thoroughly assessed and
validated by Western blot prior to use in any protein array
format, and appropriate standards for specificity should be
established. Such standards should include evidence of a
single, appropriate sized band in immunoblot analysis of com-
plex biological samples similar to those planned for array
analysis such as cell lines or whole or microdissected tissue
samples. Assessment of a phosphospecific antibody might
also require evidence of a differential signal between control
and treated samples known to activate the pathway or end
point of interest. These same positive and negative controls
are also printed directly on each array to ensure real time
assessment of specificity. A web posting of our validated
antibodies can be found at home.ccr.cancer.gov/ncifdapro-
teomics/. A significant challenge for cooperative groups,
funding agencies, and international consortia is the genera-
tion of large comprehensive libraries of fully characterized
specific antibodies, ligands, and probes. Fortunately some
large initiatives such as those of the internationally based
Human Proteomic Organization and the Human Proteome
Resource in Sweden and individual investigators are begin-
ning efforts to provide the scientific community with critical
antibody resources (57–59).
Another issue faced in research using human tissues is
small tumor size and limited availability of specimens for
study. While techniques such as laser capture microdissec-
tion and RNA amplification allow one to utilize biopsy speci-
mens and small tumors for study, it will be important that
future clinical trials incorporate tissue accrual components to
allow for the facile evaluation by molecular techniques.
REFERENCE STANDARD DEVELOPMENT
Perhaps the biggest challenge facing the widespread use of
the RPA in the clinical laboratory setting is the standardization
of each step and process involved in array production, bioin-
formatic analysis, and ensuring that tissue is processed and
handled rapidly and optimally. A recent assessment of the
gene expression microarray literature found that there is little
standardization in the field with regard to the methods, anal-
ysis, and controls used and also data validation (60). These
issues often prevent productive data comparisons between
laboratories and platforms and between experiments sepa-
rated in time. This is a particularly relevant issue with regard to
the analysis of clinical trial specimens by protein arrays where
accrual of samples may occur over extended periods of time
and analysis may require the use of multiple arrays to accom-
modate all samples for a particular study. In addition to the
standardization of tissue handling techniques and sample
preparation protocols, development of a universal reference
standard that could be deposited onto every array would
allow one to identify and compensate for variation in instru-
mentation, reagents, samples, and operators in different lab-
oratory settings and across time.
Ideally an RPA reference standard would serve as a univer-
sal positive control for the staining process and antibody
validation and also be incorporated into data analysis. A good
quality reference standard should be renewable, reproducible
on a large scale, reliable across a broad range of end points,
and stable over long periods of time. A reference standard
should also resemble the test samples as closely as possible
(61). Our group has assessed various types of source mate-
rials for use as a reference standard on our reverse phase
protein array platform. Human tissue extracts, although es-
sentially identical to our test samples, are not renewable or
routinely available in large enough quantities for large scale
reference standard production. We also found that any par-
ticular tissue extract often does not provide reliable signal for
all phosphospecific end points of interest in our profiling
studies. Theoretically multiple tissue extracts could be com-
bined into a reference standard to overcome this problem, but
this only serves to compound the problems of large scale
production and renewability. Alternatively extracts from a
wide variety of treated cell lines can be purchased or pro-
duced in large quantities, but they share the same problems
of long term reproducibility and stability found with tissue
extracts.
In our laboratory, the use of tissue extracts or lysates from
treated cells as reference standards has proven most useful
as controls for antibody validation and as positive controls for
antibody staining on reverse phase arrays (Fig. 3B). Ultimately
we have chosen to develop a reference standard containing
phosphorylated peptides specific for each of the antibodies
routinely used in our profiling studies (Fig. 6). Phosphopep-
tides represent an invariant, renewable, scalable, and repro-
ducible source material for a high quality reference lysate.
Since they are often the immunogen source itself, they bind
probe antibodies with high affinity. The peptides can be
printed in mixtures on arrays in extended dilution curves and
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be used to develop a reference calibration curve (Fig. 6). For
routine clinical implementation, much like how an ELISA is
used, each phosphospecific analyte measurement for any
experimental sample that falls into the linear range of the
calibrant can be converted into reference standard units
based on the calibrant and the dilution factor. The use of a
universal reference standard on every array produced in a
single facility or a number of different laboratories will facilitate
normalization and comparison of test samples across time,
platforms, studies, and sites.
COMBINATORIAL TARGETED MEDICINE: THE FUTURE OF PATIENT
STRATIFICATION AND “THERANOSTICS”
The use of proteomic profiling to determine the activation
status of many dozens of phosphorylation end points and
identification of the key signaling nodes in individual tumor
tissues could lead to dramatic and significant improvements
in therapeutic efficacy and patient survival. Armed with the
information about which signaling pathways are being utilized
by the primary tumor cells, surrounding stroma, and meta-
static lesions will allow us to build specific function interaction
maps for each patient. Data produced from our patient-
matched ovarian cancer primary/metastasis series indicates
the potential need to evaluate the metastatic signaling portrait
prior to treatment selection. The metastatic signatures were
clearly very different from the primary tumor taken at the same
time at surgery, and these fingerprints appear to be virtually
patient-specific (Fig. 4). The use of bioinformatics may even-
tually allow us to understand how this information changes
and fluxes as a consequence of disease stage and treatment
choice not just within the tumors but in the surrounding cel-
lular milieu. These protein interactions are interdependent on
each other, and kinase activity at one location will affect other
kinases and substrates within a circuit. We can take advan-
tage of this fact so that we can imagine a future in which
targeting a number of critical nodes along the entire deranged
signal pathway can result in an outcome with a higher poten-
tial for efficacy and lower toxicity (62). Recent mathematical
modeling experiments have indicated that, through the selec-
tion of multiple and specific signaling interconnections, a
large supra-additive synergy can be achieved by inhibiting
specific interdependent “nodes” simultaneously (63, 64). This
finding is significant based on the patient-specific signaling
heterogeneity revealed in actual patient tissue portraits as
outlined previously.
The phosphoproteome profiled using RPAs may play a
dominant and key role in personalized medicine as the aber-
rant function of protein kinases are often at the center of many
diseases, including cancer (65–73). The ability to develop a
portrait built on the activation states of the drug targets them-
selves represents the power of theranostics (therapeutic drug
targets that also are diagnostic biomarkers, such as ErbB2)
for cancer and disease treatment. Drug discovery efforts fo-
cusing on the development of small molecular weight com-
pounds and biologic agents that can mitigate and modulate
specific kinase activity is an intense area of focus for industry
due to their key roles in cancer and biology (74–79). On the
basis of proteomic and genomic portraits of the disease, an
individualized selection of therapeutic combinations that best
FIG. 6. Phosphopeptide reference standard development. Antibody-specific phosphorylated peptides can be used as components of a
reference standard for reverse phase protein arrays. This example shows phosphorylated peptides printed in 24-point dilution curves on the
arrays at a starting concentration of 1 g/ml. Peptides were printed alone or in mixtures. The reference lysate sample was composed of whole
prostate tumor tissue or peripheral blood lymphocytes. Three different mixtures of peptides were added to determine whether the antibodies
could detect peptides arrayed in mixtures. Mixture 1: pCREB, pSMAD, pFADD, pPTP1C, and pc-Cbl; Mixture 2: pCREB, pAkt, pSMAD-1, and
pENOS; Mixture 3: all nine peptides. The left panel represents an array probed with anti-phospho-c-Cbl Y700 antibody (BD Transduction
Laboratories Inc.), and the right panel represents a duplicate array stained with anti-phospho-Akt Ser-473 antibody (Cell Signaling Technology
Inc.). p, phosphorylated; CREB, cAMP-response element-binding protein; FADD, Fas-associated death domain; PTP, protein tyrosine
phosphatase; ENOS, endothelial nitric-oxide synthase. SMAD, human homolog of mothers against decapentaplegic; PTPIC, protein tyrosine
phosphatase.
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target the protein network for that specific patient can be
selected and used, resulting in a paradigm shift in patient
treatment and disease management.
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